Key facts
- It has raised $14.8M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Holley Group, Zhongshan Health Base Group, Beijing Huafang Investment Co., Panacea Capital (California), Yabao Pharmaceutical Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Fanen Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Fanen Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fanen Biotechnology
Manufacturer of tumor immunotherapy drugs aims to improve survival and quality of life for cancer patients. The company's offerings feature personalized CAR-T, TCR-T cell therapies, tumor vaccines, and immune checkpoint inhibitors, combined with proprietary diagnostics and GMP-grade production capabilities, which help hospitals and cancer treatment centers access tailored and effective immunotherapies, enabling the precise and efficient treatment of solid tumors.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2016
- Website
- fineimmu.com/
- Ownership
- Privately Held (backing)
Fanen Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fanen Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fanen Biotechnology in its N-PORT filings yet. We sweep new filings monthly.